Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?
Menée à partir des données des registres néerlandais des cancers portant sur 2 295 patientes atteintes d'un cancer du sein ER+ diagnostiqué entre l'âge de 45 et 50 ans, cette étude évalue l'efficacité, du point de vue de la survie sans récidive et de la survie globale, d'un traitement adjuvant à base d'inhibiteurs de l'aromatase ou de tamoxifène, après une chimiothérapie
Over the last decade, we have made notable strides in optimizing adjuvant endocrinetherapy as the cornerstone of treatment for women with steroid receptor-positive subtypesof early stage breast cancer. Aromatase inhibitors(AI) are well-established as standard of care for postmenopausal women, and extended durationsfor up to 10 years havebeen shown to improve outcomes. Thepivotal SOFTand TEXT trials showedstatistically significant improvement in disease free survival (DFS) with use of ovarian function suppression (OFS) with the AI, exemestane, or with OFS plus tamoxifen compared to tamoxifen in high-risk premenopausal women